What does published research say about BPC-157 and the heart?

Published August 22, 2026 · Artemis Labs

BPC-157 and the cardiovascular system — answer capsule: BPC-157 is a 15-amino-acid peptide first identified as a fragment of a protein in human gastric juice. Researchers have studied it in rats across four cardiovascular topics: heavy bleeding and blood clots, disturbed heart rhythm, changes in the wall of the aorta (the body’s largest artery), and heart muscle itself. All of that work is animal models or laboratory tissue. No published Phase II or Phase III human trial shows BPC-157 doing anything for a heart condition, so none of this research describes an effect in people.

Key findings

• A 2026 review by Sikiric and colleagues (PMID 41901308) placed the cardiovascular animal work under one idea, cytoprotection — keeping cells alive and working while under stress — and applied it to models of hemorrhage (bleeding the body struggles to stop) and thrombosis (a clot blocking a vessel).
• A second 2026 Sikiric review (PMID 41754776) covered arrhythmia models, animals whose hearts were made to beat irregularly, and discussed BPC-157 alongside the conventional classes of antiarrhythmic drugs.
• Smoday and colleagues (2026, PMID 41599787) used an infrared-light method, FTIR, to characterise the aortic wall in rats after one adrenal gland was surgically removed.
• Staresinic and colleagues (2022, DOI: 10.3390/biomedicines10123221) reviewed BPC-157 across three muscle types, including a dedicated section on heart muscle.

What is BPC-157, in one paragraph?

BPC-157 is a chain of 15 amino acids (GEPPPGKPADDAGLV). Amino acids are the building blocks of proteins, and a short chain of them is called a peptide. This sequence comes from a protein found in human gastric juice, the fluid the stomach makes to digest food. Its molecular weight is 1,419.54 g/mol and its CAS number is 137525-51-0. One structural detail draws attention: three proline residues sit in a row near the front of the chain, and published work reports the peptide staying intact in human gastric juice for more than 24 hours, unusual for an unmodified small peptide. The BPC-157 research peptide Artemis Labs supplies is a lyophilized powder tested at ≥99% purity by reverse-phase HPLC, sold for laboratory research only.

What do the bleeding and clotting studies actually look at?

Two words show up constantly here, and neither is obvious to a first-time reader. Hemorrhage means bleeding that is heavy or hard to stop. Thrombosis means a clot has formed inside a blood vessel and is blocking flow. They are close to opposites: blood escaping where it should not, versus blood jamming where it should be moving.

The 2026 Sikiric review (PMID 41901308) does not treat them as separate problems. It groups the animal work under cytoprotection, the idea that a compound can help cells hold up under stress rather than acting on one specific target. It is a review of other researchers’ experiments in rats with surgically or chemically induced conditions. Nothing in it tests a person.

What is an arrhythmia, and what did the second review cover?

A healthy heart beats in a steady rhythm because electrical signals travel through it in a set order. When those signals misfire, the rhythm turns irregular — too fast, too slow, or out of sequence. That is an arrhythmia.

The second 2026 Sikiric review (PMID 41754776) surveyed BPC-157 in animal arrhythmia models and set the findings next to the established classes of antiarrhythmic drugs, the medicines already approved to steady heart rhythm in people. Placing a research compound beside approved drugs organises a literature review. It does not show the compound behaves like them, and the review is not a human trial.

What did the aortic wall study measure?

The Smoday 2026 paper (PMID 41599787) has a title that hides a fairly simple experiment. Taking it apart:

• Aortic wall — the aorta is the largest artery in the body, carrying blood away from the heart. Its wall is layers of muscle and connective tissue.
• Remodelling — that wall’s structure changing over time, which blood vessels do in response to pressure, injury, or hormone shifts.
• Unilateral adrenalectomy — surgical removal of one of the two adrenal glands. These sit on top of the kidneys and make hormones that regulate blood pressure and salt balance, so removing one puts a rat’s cardiovascular system under a controlled hormonal stress.
• FTIR — Fourier-transform infrared spectroscopy. Infrared light passes through a tissue sample and different chemical bonds absorb different wavelengths, so the pattern of absorption describes the tissue’s chemical makeup.

The study is a chemical characterisation, then: what the aortic wall looked like at the level of its molecules in rats after that operation. Our source record documents the method and the model rather than a numeric result, and we would rather say so than fill the gap with a number we cannot verify.

Where does heart muscle come into it?

The body has more than one kind of muscle: skeletal muscle you move on purpose, smooth muscle lining organs and blood vessels, and heart muscle, which never rests. The Staresinic 2022 review covered animal models across all three, with heart muscle as one of its sections, which makes it the bridge between the tendon-and-muscle literature and the cardiovascular side. Our page on BPC-157 and muscle research stays on that thread.

Blood vessels are the other neighbouring area. Yildirim and colleagues (2026, PMID 42123221) reported concentration-dependent relaxation of human internal mammary artery tissue in a tissue bath, where a strip of donated vessel is suspended in fluid outside the body. That is the first human-tissue mechanism data here, and it is not a clinical trial. We cover it on BPC-157 and blood vessel research, and the wider 2026 picture in our preclinical foundation and human-tissue evidence review.

Does the electrolyte research belong here?

Only as background. Electrolytes are minerals in the blood, potassium and sodium among them, that carry the electrical charge nerve and heart cells use to signal. When their levels swing far out of range, heart rhythm is one of the first things affected. Medvidovic Grubisic and colleagues (2026, PMID 41832718) studied BPC-157 in rats with severe electrolyte disturbance. We list it because it sits near the rhythm work, not as a cardiovascular finding.

What the research does not show

There is no published Phase II or Phase III human efficacy trial of BPC-157 for any use, cardiovascular or otherwise. Pilot human safety work is referenced in the 2026 reviews by Mendias (PMID 41966639) and Mayfield (PMID 41476424), but a safety pilot is not an efficacy trial. Every statement anyone makes about what BPC-157 does for a heart is extrapolated from rats or from tissue in a dish.

Three more limits matter. BPC-157 has no single defined receptor and no canonical binding assay, so no agreed laboratory test declares a response positive or null. Effect sizes vary substantially with model, dose, route, and species, which makes papers hard to compare. And most of the work above sits in review articles, whose strength depends entirely on the animal studies underneath them.

On status: BPC-157 is not an FDA-approved drug for any use. It was placed on an interim 503A compounding category in September 2023, removed from that list on September 27, 2024 after the nominator withdrew, and is now before the Pharmacy Compounding Advisory Committee. A July 2026 FDA advisory committee vote was non-binding, so the regulatory picture is unsettled. BPC-157 also appears on the WADA Prohibited List under Section S2, prohibited at all times.

Frequently asked questions

Has BPC-157 been tested in people for a heart condition?

No. There is no published Phase II or Phase III human efficacy trial for any use. The cardiovascular literature is animal models and laboratory tissue.

What does cytoprotection mean in these papers?

It is the framing the 2026 Sikiric review uses: a compound helping cells stay functional under stress, rather than acting through one narrow target. It describes how the authors organised their animal findings.

Why do bleeding and clotting studies appear in the same review?

Because that review groups them under the cytoprotection idea rather than as two unrelated problems. Both are induced animal models, not patients.

Can a competing athlete use BPC-157?

Not without risk. It sits in Section S2 of the WADA Prohibited List, prohibited at all times, so a tested athlete faces an anti-doping violation regardless of source or intent.

References

1. Sikiric P, et al. (2026). Cytoprotection framing for hemorrhage and thrombosis, animal models. PMID 41901308
2. Sikiric P, et al. (2026). Arrhythmia-model review alongside conventional antiarrhythmic classes. PMID 41754776
3. Smoday IM, et al. (2026). FTIR characterisation of aortic wall remodelling after unilateral adrenalectomy in rats. PMID 41599787
4. Staresinic M, et al. (2022). Review across striated, smooth, and heart muscle models. DOI: 10.3390/biomedicines10123221
5. Medvidovic Grubisic M, et al. (2026). Severe electrolyte disturbance in rats. PMID 41832718
6. Yildirim S, et al. (2026). Endothelium-dependent, nitric-oxide-mediated relaxation of human internal mammary artery, ex vivo. PMID 42123221
7. Mendias CL, Awan TM. Sports Med. 2026. PMID 41966639
8. Mayfield CK, et al. Am J Sports Med. 2026. PMID 41476424

Methodology: this page draws only on the peer-reviewed animal, review, and tissue studies listed above, taken from the Artemis Labs BPC-157 research record; citations last verified August 22, 2026.

All compounds sold by Artemis Labs are for laboratory research use only. Nothing on this page is medical advice, and no statement has been evaluated by the FDA.